Literature DB >> 30209099

Do PCSK9 inhibitors reduce cardiovascular events?

Michael R Kolber1, Tony Nickonchuk2, Ricky Turgeon3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30209099      PMCID: PMC6135138     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  12 in total

Review 1.  Coenzyme Q10 supplementation in the management of statin-associated myalgia.

Authors:  Jason T Tan; Arden R Barry
Journal:  Am J Health Syst Pharm       Date:  2017-06-01       Impact factor: 2.637

2.  Antidrug Antibodies in Patients Treated with Alirocumab.

Authors:  Eli M Roth; Anne C Goldberg; Alberico L Catapano; Albert Torri; George D Yancopoulos; Neil Stahl; Aurélie Brunet; Guillaume Lecorps; Helen M Colhoun
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

3.  Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care.

Authors:  G Michael Allan; Adrienne J Lindblad; Ann Comeau; John Coppola; Brianne Hudson; Marco Mannarino; Cindy McMinis; Raj Padwal; Christine Schelstraete; Kelly Zarnke; Scott Garrison; Candra Cotton; Christina Korownyk; James McCormack; Sharon Nickel; Michael R Kolber
Journal:  Can Fam Physician       Date:  2015-10       Impact factor: 3.275

4.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Authors:  Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

5.  Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Authors:  Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

7.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

Review 8.  2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.

Authors:  Todd J Anderson; Jean Grégoire; Glen J Pearson; Arden R Barry; Patrick Couture; Martin Dawes; Gordon A Francis; Jacques Genest; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence A Leiter; Eva Lonn; G B John Mancini; Ruth McPherson; Daniel Ngui; Paul Poirier; John L Sievenpiper; James A Stone; George Thanassoulis; Richard Ward
Journal:  Can J Cardiol       Date:  2016-07-25       Impact factor: 5.223

9.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  Lancet       Date:  2014-10-01       Impact factor: 79.321

Review 10.  Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.

Authors:  Aris Karatasakis; Barbara A Danek; Judit Karacsonyi; Bavana V Rangan; Michele K Roesle; Thomas Knickelbine; Michael D Miedema; Houman Khalili; Zahid Ahmad; Shuaib Abdullah; Subhash Banerjee; Emmanouil S Brilakis
Journal:  J Am Heart Assoc       Date:  2017-12-09       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.